Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Cirrhosis

  Free Subscription


Articles published in Proc Natl Acad Sci U S A

Retrieve available abstracts of 6 articles:
HTML format



Single Articles


    March 2022
  1. KAPS L, Huppertsberg A, Choteschovsky N, Klefenz A, et al
    pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages.
    Proc Natl Acad Sci U S A. 2022;119:e2122310119.
    PubMed     Abstract available


    July 2021
  2. NISHIO T, Koyama Y, Liu X, Rosenthal SB, et al
    Immunotherapy-based targeting of MSLN(+) activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    April 2021
  3. NISHIMURA N, De Battista D, McGivern DR, Engle RE, et al
    Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    March 2021
  4. PICCOLO P, Ferriero R, Barbato A, Attanasio S, et al
    Up-regulation of miR-34b/c by JNK and FOXO3 protects from liver fibrosis.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    December 2020
  5. YUEH MF, He F, Chen C, Vu C, et al
    Triclosan leads to dysregulation of the metabolic regulator FGF21 exacerbating high fat diet-induced nonalcoholic fatty liver disease.
    Proc Natl Acad Sci U S A. 2020;117:31259-31266.
    PubMed     Abstract available


    November 2020
  6. SCHIERWAGEN R, Dietrich P, Klein S, Uschner FE, et al
    beta-Arrestin2 is increased in liver fibrosis in humans and rodents.
    Proc Natl Acad Sci U S A. 2020;117:27082-27084.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: